Výsledky vyhledávání - "Matthew Miera"

Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial

Autor: Michel Delforge, Paula Rodríguez Otero, Nina Shah, Olga Moshkovich, Julia Braverman, Devender S. Dhanda, Sally Lanar, Jennifer Devlen, Matthew Miera, Heather Gerould, Timothy B. Campbell, Nikhil C. Munshi

Publikováno v: Leukemia Research. 129:107074

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8117febce698bb52c954ac319e3c1c70
https://doi.org/10.1016/j.leukres.2023.107074

Zobrazit plný text záznamu

Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial

Autor: Nina Shah, Michel Delforge, Jesus San-Miguel, Olga Moshkovich, Julia Braverman, Devender S. Dhanda, Sally Lanar, Matthew Miera, Agnes Williams, Ryan Murphy, Jennifer Devlen, Kristen Hege, Timothy B. Campbell, Nikhil C. Munshi

Publikováno v: Leukemia Research. 120:106921

OBJECTIVE: To understand the experience of patients with relapsed and refractory multiple myeloma (RRMM) receiving idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in the pivotal, phase

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57950ba4c5eb388fab40d8272f1ad9c2
https://doi.org/10.1016/j.leukres.2022.106921

Zobrazit plný text záznamu

Interviews of Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Lisocabtagene Maraleucel (liso-cel) Trials on Their Treatment Experience for 3 Months after Infusion

Autor: Matthew Miera, Tanya Siddiqi, Olga Moshkovich, Julia Braverman, Jennifer Devlen, Gilles Salles, Ulrich Jaeger, Sally Lanar, Selam Shah, Fei Fei Liu

Publikováno v: Blood. 138:4098-4098

Pts with R/R LBCL had rapid and durable responses with liso-cel, a CD19-directed chimeric antigen receptor (CAR) T cell therapy. Previous qualitative research showed high perceptions of unmet pretreatment needs and largely positive pt experiences imm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5bf1654f1c1e95763eb1deb0d374e4ab
https://doi.org/10.1182/blood-2021-151823

Zobrazit plný text záznamu

Idecabtagene Vicleucel (ide-cel, bb2121), a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy: Qualitative Analyses of Post-Treatment Interviews (Months 6-24) for Patients with Relapsed and Refractory Multiple Myeloma in the Karmma Clinical Trial

Autor: Nikhil C. Munshi, Timothy B. Campbell, Paula Rodriguez-Otero, Olga Moshkovich, Julia Braverman, Matthew Miera, Nina Shah, Devender Dhanda, Jennifer Devlen, Heather Gerould, Michel Delforge, Sally Lanar

Publikováno v: Blood. 138:3041-3041

Introduction: Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell therapy, is approved by the US FDA for the treatment of adult patients (pts) with relapsed and refractory multiple myel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7e263a00ca0de4e2ca09d635d9af6e6c
https://doi.org/10.1182/blood-2021-145166

Zobrazit plný text záznamu

Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy: Qualitative analyses of pretreatment patient interviews in the KarMMa trial

Autor: Kristen Hege, Olga Moshkovich, Triza Brion, Jennifer Devlen, Selam Shah, Timothy B. Campbell, Julia Braverman, Matthew Miera

Publikováno v: Journal of Clinical Oncology. 38:155-155

155 Background: Outcomes remain poor in triple-class exposed (to an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody) patients (pts) with relapsed and refractory multiple myeloma (RRMM), and there is no standard of care. Ide-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::18a31d4b777a521c6de774435c6e7b49
https://doi.org/10.1200/jco.2020.38.29_suppl.155

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání